DK3083678T3 - Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser - Google Patents

Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser Download PDF

Info

Publication number
DK3083678T3
DK3083678T3 DK14825462.6T DK14825462T DK3083678T3 DK 3083678 T3 DK3083678 T3 DK 3083678T3 DK 14825462 T DK14825462 T DK 14825462T DK 3083678 T3 DK3083678 T3 DK 3083678T3
Authority
DK
Denmark
Prior art keywords
myeloproliferative
disinfecting
procedures
lymphoproliferative disorders
lymphoproliferative
Prior art date
Application number
DK14825462.6T
Other languages
English (en)
Inventor
Adrianus Quirinus Bakker
Mette Deborah Hazenberg
Hergen Spits
Tim Beaumont
Marijn Aletta Gillissen
Martijn Kedde
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Application granted granted Critical
Publication of DK3083678T3 publication Critical patent/DK3083678T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
DK14825462.6T 2013-12-17 2014-12-17 Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser DK3083678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197882 2013-12-17
PCT/NL2014/050873 WO2015093949A2 (en) 2013-12-17 2014-12-17 Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

Publications (1)

Publication Number Publication Date
DK3083678T3 true DK3083678T3 (da) 2019-06-17

Family

ID=49765419

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14825462.6T DK3083678T3 (da) 2013-12-17 2014-12-17 Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser

Country Status (13)

Country Link
US (3) US10556963B2 (da)
EP (2) EP3083678B1 (da)
JP (1) JP6800751B2 (da)
KR (3) KR20240042192A (da)
CN (2) CN113072644A (da)
AU (1) AU2014367398B2 (da)
BR (1) BR112016014072B1 (da)
CA (1) CA2933960A1 (da)
DK (1) DK3083678T3 (da)
EA (1) EA201691130A8 (da)
ES (1) ES2729057T3 (da)
MX (2) MX2016008109A (da)
WO (1) WO2015093949A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083678B1 (en) 2013-12-17 2019-04-03 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
BR112017027677A2 (pt) 2015-06-24 2018-08-28 Aimm Therapeutics Bv peptídeo, composto, mólecula de ácido nucleico, vetor, uso de um peptídeo, anticorpo, composição imunogênica, kit, métodos para determinar se um indivíduo tem lma e para produzir uma célula imune e/ou anticorpo, veículo de dispensação de gene, e, célula hospedeira
CN109467602A (zh) * 2018-11-05 2019-03-15 暨南大学 与cxcr4结合的人源蛋白及其应用
BR112022013601A2 (pt) 2020-01-10 2022-09-13 Kling Biotherapeutics B V Anticorpos específicos de caderina epitelial

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US7399847B1 (en) 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
CA2607930C (en) 2005-05-11 2012-08-21 Dinona Inc. Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110262474A1 (en) * 2007-07-23 2011-10-27 Xiaohan Du Chimeric HIV Antigens
WO2009051974A1 (en) 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP3360879A1 (en) * 2009-02-05 2018-08-15 ImmunoGen, Inc. Benzodiazepine derivatives as cytotoxic agents
CN102405237A (zh) 2009-03-06 2012-04-04 卡罗拜奥斯制药公司 利用EphA3抗体治疗白血病和慢性骨髓增生性疾病
AR077756A1 (es) 2009-07-15 2011-09-21 Genentech Inc Anticuerpos especificos para bacterias gram-positivas
EP2665749B1 (en) 2011-01-19 2016-01-13 Cantargia AB Anti-il1rap antibodies and their use for treating solid tumours
EA026153B1 (ru) 2011-11-09 2017-03-31 Бристол-Майерс Сквибб Компани Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
CA2892992A1 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3083678B1 (en) 2013-12-17 2019-04-03 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

Also Published As

Publication number Publication date
KR20220108202A (ko) 2022-08-02
EP3572425A1 (en) 2019-11-27
EP3083678A2 (en) 2016-10-26
MX2016008109A (es) 2017-01-13
EA201691130A8 (ru) 2018-08-31
JP6800751B2 (ja) 2020-12-16
WO2015093949A3 (en) 2016-01-14
BR112016014072B1 (pt) 2023-12-26
ES2729057T3 (es) 2019-10-30
US11629200B2 (en) 2023-04-18
EA201691130A1 (ru) 2016-11-30
MX2019014301A (es) 2020-02-03
CN106062002A (zh) 2016-10-26
EP3083678B1 (en) 2019-04-03
US20160326261A1 (en) 2016-11-10
WO2015093949A2 (en) 2015-06-25
KR102426195B1 (ko) 2022-07-28
BR112016014072A8 (pt) 2020-11-03
CN106062002B (zh) 2021-05-04
JP2017502664A (ja) 2017-01-26
KR20240042192A (ko) 2024-04-01
BR112016014072A2 (pt) 2018-01-09
US20200239593A1 (en) 2020-07-30
AU2014367398A1 (en) 2016-07-07
US10556963B2 (en) 2020-02-11
AU2014367398B2 (en) 2020-06-18
CA2933960A1 (en) 2015-06-25
KR20160117433A (ko) 2016-10-10
US20230242667A1 (en) 2023-08-03
CN113072644A (zh) 2021-07-06

Similar Documents

Publication Publication Date Title
BR112017002511A2 (pt) sistemas e métodos de almofada terapêutica
DK3197354T3 (da) Medicinsk anordning
DK3202305T3 (da) Engangsendoskop og system
DK3705102T3 (da) Patientløftesystem
DK2764881T3 (da) System til medicinsk behandling
DK2950764T3 (da) Sårhage/stabilisator til overskydende og/eller overflødigt væv
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3068505T3 (da) Spillesystem og -fremgangsmåde
DK2975358T3 (da) Trinbrætanordning
DK3231016T3 (da) Fotovoltaikmodul og fotovoltaiksystem
FI20135231A (fi) Potilasalusta
BR302014001196S1 (pt) Configuração aplicada em dispositivo médico
DK3083678T3 (da) Midler og fremgangsmåder til at modvirke myeloproliferative eller lymfoproliferative forstyrrelser
DK2968625T3 (da) Steriliseringsreaktor og fremgangsmåde
DK3096610T3 (da) Æggebrydningssystemer og -fremgangsmåder
DK2964623T3 (da) Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik
DK3072884T3 (da) 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
BR302014001194S1 (pt) Configuração aplicada em dispositivo médico
BR302014001193S1 (pt) Configuração aplicada em dispositivo médico
DE112015007021A5 (de) Matratzensystem
FI20145982A (fi) Potilasalusta
BR302014001192S1 (pt) Configuração aplicada em dispositivo médico
UA31971S (uk) Анатомічний матрац
BR302014002719S1 (pt) Configuração aplicada em cadeira
BR302014002222S1 (pt) Configuração aplicada em cadeira